🔴 Adaptive Biotechnologies is trading 4.4% down in pre-market — no clear catalyst identified

Adaptive Biotechnologies is trading 4.4% down at $23.51 in pre-market, with no clear direct catalyst identified.

• It closed at $24.60 on August 5; no fresh company-specific announcement, earnings release, regulatory action, or analyst change was found for August 6.
• The latest reported results were released July 29, including $71.6 million in second-quarter revenue and raised MRD guidance, making them unlikely to explain this morning’s move.
• Nasdaq futures were down 0.55% amid technology-sector weakness, but that is insufficient to establish a direct catalyst.